Ulcerative colitis (UC) is a lifelong condition marked by painful flares, limited drug options, and a gut microbiota in disarray. This 21-day trial set out to test whether a daily dose of Lactobacillus acidophilus LA85 could deliver measurable relief in the DSS treated mouse model with UC.

​Wecare Probiotics' Bifidobacterium animalis subsp. lactis BLa80 has made history as the first probiotic strain from mainland China to enter the Infant Whitelist with both self-affirmed GRAS and FDA GRAS status.

The global health landscape is undergoing a significant transformation, marked by a dramatic increase in overweight and obesity rates. According to the World Health Organization (WHO), in 2025 this year, a staggering one in eight people worldwide were living with obesity.

Wecare Probiotics announced a landmark strategic partnership with Dassault Systèmes, the world leader in Product Lifecycle Management (PLM) solutions. The official signing ceremony on July 20, 2025, marks a significant milestone in Wecare' journey toward advanced digitalization and sustainable growth.

Wecare Probiotics, as a leading technological innovator, is excited to announce the significant potential of its flagship probiotic strain, Lacticaseibacillus Rhamnosus LRa05, in advancing women's health.

July 10, 2025 – In light of World Allergy Day and the recent World Allergy Week 2025, which highlighted the critical theme of Anaphylaxis, Wecare Probiotics would like to share insights from an ongoing clinical trial (NCT06699537) involving its flagship probiotic strain, Lacticasibacillus Rhamnosus LRa05.